Details for Patent: 9,517,226

Which drugs does patent 9,517,226 protect, and when does it expire?

Patent 9,517,226 protects ENTRESTO and is included in one NDA.

This patent has thirty-eight patent family members in twenty-six countries.

Summary for Patent: 9,517,226

Title:	Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Abstract:	The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p -phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p -phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling.
Inventor(s):	Schumacher; Christoph (Bettingen, CH), Holbro; Thomas (Basel, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	14/422,855
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,517,226

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-001	Jul 7, 2015		RX	Yes	No						TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-002	Jul 7, 2015		RX	Yes	No						TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-003	Jul 7, 2015		RX	Yes	Yes						TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION

Foreign Priority and PCT Information for Patent: 9,517,226

PCT Information
PCT Filed	August 22, 2013	PCT Application Number:	PCT/EP2013/067472
PCT Publication Date:	February 27, 2014	PCT Publication Number:	WO2014/029848

International Family Members for US Patent 9,517,226

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013304949
Brazil	112015003067
Canada	2882771
Chile	2015000426
China	104602711
China	108685889
Denmark	2887961